HBY Hybridon

Hybridon to Present at Two Upcoming Conferences - Adjuvants Panel at Phacilitate Vaccine Forum Fall 2004; Corporate Overview at the 6th Annual Massachusetts Opportunities in Biotechnology Investor Conference - CAMBRIDGE, Mass., Nov. 2 /PRNewswire-FirstCall/ -- Hybridon, Inc. (AMEX:HBY) announced today that company management will present at the Phacilitate Vaccine Forum Fall 2004 at the Hyatt Regency in Cambridge, Massachusetts. Sudhir Agrawal, D.Phil, Hybridon's President, Chief Executive Officer and Chief Scientific Officer, will deliver a presentation entitled "Synthetic DNA Adjuvants: Agonists of Toll-like Receptors" that will include a look at the Company's discovery programs and Phase 1 clinical studies for its lead 2nd-generation immunomodulatory oligonucleotide. Dr. Agrawal will also present at the 6th Annual Massachusetts Opportunities in Biotechnology Investment Conference at 1:30 p.m. (ET) on Thursday, November 4, 2004 at the Logan Airport Hilton Hotel in Boston, MA. He will provide an overview of the Company and an update on clinical and business activities. Hybridon, Inc. is a leader in the discovery and development of novel therapeutics based on synthetic DNA. The Company's focus is to develop therapeutics independently and with partners based on two proprietary technology platforms. The first platform includes a variety of novel synthetic DNA structures (immunomodulatory oligonucleotide or IMOTM motifs) that act to modulate responses of the immune system. The second platform uses synthetic DNA to block the production of disease-causing proteins at the cellular level (antisense technology). Licensees of Hybridon's technology include Isis Pharmaceuticals, Inc., MethylGene, Inc., Aegera Therapeutics, Inc., Migenix Inc., Epigenesis Pharmaceuticals, Inc., The Immune Response Corporation, and Alnylam Pharmaceuticals, Inc. The Company is conducting clinical trials in oncology patients with HYB2055 (IMOxine(TM)), a 2nd-generation IMO, and with GEM(R)231 (a 2nd-generation antisense oligonucleotide targeted to protein kinase A) in combination with irinotecan. Additional information about Hybridon is available at http://www.hybridon.com/. This press release contains forward-looking statements concerning Hybridon that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words, "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Hybridon's actual results to differ materially from those indicated by such forward-looking statements, including risks as to whether the Company will be able to enter into new collaborations or maintain its existing collaborations and whether such collaborations will be successful; whether the Company will commence clinical trials; whether results obtained in preclinical studies or early clinical trials will be indicative of results obtained in future preclinical studies or clinical trials, or warrant further clinical trials and product development; whether products based on Hybridon's technology will advance through the clinical trial process and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if such products receive approval, they will be successfully distributed and marketed; whether the patents and patent applications owned or licensed by Hybridon will protect the Company's technology and prevent others from infringing it; whether Hybridon's cash resources will be sufficient to fund product and clinical development; and such other important factors as are set forth under the caption "Risk Factors" in Hybridon's Quarterly Report on Form 10-Q filed on August 6, 2004, which important factors are incorporated herein by reference. Hybridon disclaims any intention or obligation to update any forward-looking statements. Contacts: Hybridon, Inc. Euro RSCG Life NRP 617-679-5500 x 5517 212-845-4268 Robert G. Andersen Robert Stanislaro (media) E-mail: 212-845-4269 Brian Ritchie (investors) DATASOURCE: Hybridon, Inc. CONTACT: Robert G. Andersen of Hybridon, Inc., +1-617-679-5500, ext. 5517, ; or Media - Robert Stanislaro, +1-212-845-4268, or Investors - Brian Ritchie, +1-212-845-4269, both of Euro RSCG Life NRP, for Hybridon, Inc. Web site: http://www.hybridon.com/

Copyright